Accelerated Drug Approval and Trial Design

The 17th International Workshop on Multiple Myeloma (iwMyeloma 2024) was held recently in Miami, FL, and brought together experts from around the world to discuss the latest updates, challenges, and research in the field.

In this episode, Ola Landgren, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, Suzanne Lentzsch, MD, PhD, Columbia University, New York, NY, Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, and Suzanne Trudel, MSc, MD, Princess Margaret Cancer Centre, Toronto, Canada, discuss the use of various agents in myeloma, including the suitability of bisphosphonates to treat bone disease, and updates with the use of isatuximab and belantamab mafodotin. The experts also share their thoughts on the benefits of using measurable residual disease (MRD) as a surrogate endpoint in clinical trials.

The post iwMyeloma 2024 Session I: approaching bone disease, clinical trial updates & the value of MRD as an endpoint in trials appeared first on VJHemOnc.